Stifel reaffirms its 'buy' recommendation on bioMérieux, while raising its target price from 110 to 124 euros, in the wake of an update to its EPS estimates (+2.5% for 2024, but -0.7% for 2025).

The broker explains that this update follows the French in vitro diagnostics specialist's Investor Day (CMD) the previous day, the first in years, marked by the presentation of its five-year plan.

From this meeting, Stifel highlights the objective of a 'well-balanced capital allocation between long-term investment in the company, dividend policy and value-creating external growth (M&A) possible thanks to low debt'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.